Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remimazolam vs Propofol vs Sevoflurane on NETs and Inflammation After NSCLC Surgery
ChiCTR2600119997Phase 4Recruiting
- Sponsor
- Soochow University
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in non-small cell lung cancer (NSCLC) comparing Remimazolam group, Propofol group and Sevoflurane group (3 arms). Primary endpoint: Serum NETosis-specific marker (myeloperoxidase, MPO). Started Mar 2026; status: recruiting.
02
Drugs
remimazolampropofolsevoflurane
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2600119997.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600119997.